ProPublica’s first-of-its-kind analysis is the most detailed look yet into a rise in life-threatening complications for women ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for ...

Study performed at the Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain.

Although the 65 patients in the aPTT group received more heparin than the 66 patients in ... and therapeutic in the aPTT group, there were no significant differences in recurrent venous ...

The tcPHG with the thrombin-cleavable linker peptide released heparin when incubated with thrombin, whereas there was no release from the directly crosslinked ... as starPEG may impair cell adhesion ...